查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1457962

全球幹細胞治療市場：市場規模和佔有率分析（依類型、細胞來源和應用）、工業需求預測（截至 2030 年）

Stem Cell Therapy Market Size and Share Analysis by Type, Cell Source, Application - Global Industry Demand Forecast to 2030
出版日期: | 出版商: Prescient & Strategic Intelligence | 英文 280 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2023年全球幹細胞治療市場規模將達3.061億美元，2030年將達9.108億美元。

生長促進因子

市場成長的主要驅動力是骨科疾病、創傷、神經系統疾病和自體免疫疾病（狼瘡、多發性硬化症、慢性阻塞性肺病、中風、帕金森氏症、肌萎縮側索硬化症等）的患病率不斷上升。

此外，隨著對幹細胞治療的興趣增加，對幹細胞庫的需求也在增加，預計這將成為未來市場擴張的驅動力。

此外，研究的進步和對個人化藥物的日益關注也可能在未來幾年推動該行業的發展。

異體幹細胞療法佔有最大佔有率

異體幹細胞療法將在2023年佔據最大佔有率，達到60%，預計2024年至2030年將以17%的速度成長。

這是因為推進此類治療的臨床試驗數量正在增加。

同種異體移植的最大優點是沒有腫瘤細胞污染移植物。移植物也由從捐贈者獲得的免疫活性細胞組成，這可能會引發免疫移植物抗惡性腫瘤的作用。

北美地區收入佔比最大

北美將成為依地區劃分的市場領導者，到 2023 年，其佔有率將達到 55%，並且在 10 年分析期結束時將顯著增長。

這是因為該地區正在投資開發幹細胞治療方法。

亞太地區成長最快

亞太地區是成長最快的地區，其中中國是幹細胞治療的重點國家。

在本報告中，我們分析了全球幹細胞治療市場，包括市場的基本結構、最新情況、主要促進和抑制因素以及全球、依地區和主要國家的市場規模前景（價值基礎） ，2017-2030）（年），依細胞類型、細胞來源和應用劃分的詳細趨勢、當前市場競爭狀況以及主要公司概況。

目錄

第一章 調查範圍

第二章研究方法

第3章執行摘要

第四章 市場指標

第五章 產業展望

  • 市場動態
    • 趨勢
    • 促進因素
    • 抑制因素/課題
    • 促進/抑制因素影響分析
  • 新型冠狀病毒感染（COVID-19）的影響
  • 波特五力分析

第六章 世界市場

  • 概述
  • 市場收入：依類型分類（2017-2030）
  • 市場收入：依電池來源分類（2017-2030）
  • 市場收入：依應用分類（2017-2030）
  • 市場收入：依地區（2017-2030）

第七章 北美市場

  • 概述
  • 市場收入：依類型分類（2017-2030）
  • 市場收入：依電池來源分類（2017-2030）
  • 市場收入：依應用分類（2017-2030）
  • 市場收入：依國家分類（2017-2030）

第八章歐洲市場

第九章亞太市場

第十章 拉丁美洲市場

第十一章 中東和非洲（MEA）市場

第十二章 美國市場

  • 概述
  • 市場收入：依類型分類（2017-2030）
  • 市場收入：依電池來源分類（2017-2030）
  • 市場收入：依應用分類（2017-2030）

第十三章 加拿大市場

第十四章 德國市場

第十五章 法國市場

第十六章 英國市場

第十七章 義大利市場

第十八章 西班牙市場

第十九章 日本市場

第20章 中國市場

第21章 印度市場

第22章澳洲市場

第23章 韓國市場

第24章 巴西市場

第25章 墨西哥市場

第26章 沙烏地阿拉伯市場

第27章南非市場

第28章 阿拉伯聯合大公國（UAE）市場

第29章競爭格局

  • 市場參與者及其提供的產品/服務的列表
  • 主要企業競爭基準
  • 主要公司的產品基準
  • 近期策略發展狀況

第三十章 公司簡介

  • Smith & Nephew plc
  • MEDIPOST Co. Ltd.
  • Anterogen Co. Ltd.
  • CORESTEM Inc.
  • PHARMICELL Co. Ltd.
  • NuVasive Inc.
  • RTI Surgical Inc.
  • AlloSource
  • JCR Pharmaceutical Co. Ltd.
  • Takeda Pharmaceutical Company Limited

第31章附錄

簡介目錄
Product Code: 12786

The size of the stem cell therapy market was USD 306.1 million in 2023, and it will touch USD 910.8 million in 2030, with a rate of 16.9% throughout the projection period.

Growth Drivers

The key factors responsible for the advance of the market are the growing incidence of orthopedic conditions, traumatic injuries, neurological ailments, and autoimmune diseases, such as lupus, multiple sclerosis, COPD, stroke, Parkinson's disease, and ALS.

Also, with the growing familiarity of stem cell therapy, the rising requirement for stem cell banking will power the market in the future.

Moreover, the growing advances in research and a rising emphasis on customized medications will power the industry in the years to come as well.

For example, in November 2022, USD 8 million was invested by the California Institute for Regenerative Medicine in the UC San Diego Alpha Stem Cell Clinic for allowing the latter to create more-efficient stem cell therapies for the diseases, which are difficult to treat.

Allogeneic Stem Cell Therapy had the Largest Share

The largest share of 60% was held by the Allogeneic stem cell therapy in 2023, and it will power at a rate of 17% during 2024-2030.

This is because of the growth in the count of clinical trials for the advance of these kinds of treatments.

The foremost advantage of allogeneic transplantation is that there is not any contaminating tumor cell in the graft. The graft also comprises immunocompetent cells resultant from a donor, which might initiate an immune graft-against-malignancy effect.

Autologous Therapy To Grow Significantly

The autologous therapy category will have a significant growth in the future due to the little risk of rejection of graft in this treatment. People requiring high-dose of chemotherapy and radiation are frequently transplanted with autologous stem cells for replacing the bone marrow damaged by the main treatment.

Furthermore, more than a few studies, conducted in recent times are focusing on autologous HSCT have shown optimistic results for secondary progressive multiple sclerosis. The method makes use of healthy blood stem cells from the own body of a person for replacing diseased cells.

North America to have Largest Revenue Share

North America was the leader of the regional market, with a share of 55%, in 2023, and it will grow significantly by the end of this decade.

This is due to the investment being provided for the development of stem cell therapies in this region.

For example, in September 2022, a gene-therapy-focused contract development and manufacturing company Forge Biologics Inc, publicized that it has acquired a total amount of USD 90 million in a Series C financing round co-led by Drive Capital and Aisling Capital, with another unrevealed strategic investor.

APAC Region To Grow the Fastest

Ther APAC region is observing the fastest-growth, with China being a key nation concentrating on stem cell therapy.

For example, OBiO Technology Corp. Ltd., a Shanghai-based gene-and-cell-therapy-focused CRO and CDMO in January 2023, publicized that the FDA has acknowledged its GMP plasmid drug master file filings for autologous and allogenic cell therapy and stem cell therapy products and helps in reducing the time taken in communication, assessment, and analysis of the filings for related therapeutics on part of the FDA.

Table of Contents

Chapter 1. Research Scope

  • 1.1. Research Objectives
  • 1.2. Market Definition
  • 1.3. Analysis Period
  • 1.4. Market Size Breakdown by Segments
    • 1.4.1. Market size breakdown, by type
    • 1.4.2. Market size breakdown, by cell source
    • 1.4.3. Market size breakdown, by application
    • 1.4.4. Market size breakdown, by region
    • 1.4.5. Market size breakdown, by country
  • 1.5. Market Data Reporting Unit
    • 1.5.1. Value
  • 1.6. Key Stakeholders

Chapter 2. Research Methodology

  • 2.1. Secondary Research
    • 2.1.1. Paid
    • 2.1.2. Unpaid
    • 2.1.3. P&S Intelligence database
  • 2.2. Primary Research
  • 2.3. Market Size Estimation
  • 2.4. Data Triangulation
  • 2.5. Currency Conversion Rates
  • 2.6. Assumptions for the Study
  • 2.7. Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Market Indicators

Chapter 5. Industry Outlook

  • 5.1. Market Dynamics
    • 5.1.1. Trends
    • 5.1.2. Drivers
    • 5.1.3. Restraints/challenges
    • 5.1.4. Impact analysis of drivers/restraints
  • 5.2. Impact of COVID-19
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Bargaining power of buyers
    • 5.3.2. Bargaining power of suppliers
    • 5.3.3. Threat of new entrants
    • 5.3.4. Intensity of rivalry
    • 5.3.5. Threat of substitutes

Chapter 6. Global Market

  • 6.1. Overview
  • 6.2. Market Revenue, by Type (2017-2030)
  • 6.3. Market Revenue, by Cell Source (2017-2030)
  • 6.4. Market Revenue, by Application (2017-2030)
  • 6.5. Market Revenue, by Region (2017-2030)

Chapter 7. North America Market

  • 7.1. Overview
  • 7.2. Market Revenue, by Type (2017-2030)
  • 7.3. Market Revenue, by Cell Source (2017-2030)
  • 7.4. Market Revenue, by Application (2017-2030)
  • 7.5. Market Revenue, by Country (2017-2030)

Chapter 8. Europe Market

  • 8.1. Overview
  • 8.2. Market Revenue, by Type (2017-2030)
  • 8.3. Market Revenue, by Cell Source (2017-2030)
  • 8.4. Market Revenue, by Application (2017-2030)
  • 8.5. Market Revenue, by Country (2017-2030)

Chapter 9. APAC Market

  • 9.1. Overview
  • 9.2. Market Revenue, by Type (2017-2030)
  • 9.3. Market Revenue, by Cell Source (2017-2030)
  • 9.4. Market Revenue, by Application (2017-2030)
  • 9.5. Market Revenue, by Country (2017-2030)

Chapter 10. LATAM Market

  • 10.1. Overview
  • 10.2. Market Revenue, by Type (2017-2030)
  • 10.3. Market Revenue, by Cell Source (2017-2030)
  • 10.4. Market Revenue, by Application (2017-2030)
  • 10.5. Market Revenue, by Country (2017-2030)

Chapter 11. MEA Market

  • 11.1. Overview
  • 11.2. Market Revenue, by Type (2017-2030)
  • 11.3. Market Revenue, by Cell Source (2017-2030)
  • 11.4. Market Revenue, by Application (2017-2030)
  • 11.5. Market Revenue, by Country (2017-2030)

Chapter 12. U.S. Market

  • 12.1. Overview
  • 12.2. Market Revenue, by Type (2017-2030)
  • 12.3. Market Revenue, by Cell Source (2017-2030)
  • 12.4. Market Revenue, by Application (2017-2030)

Chapter 13. Canada Market

  • 13.1. Overview
  • 13.2. Market Revenue, by Type (2017-2030)
  • 13.3. Market Revenue, by Cell Source (2017-2030)
  • 13.4. Market Revenue, by Application (2017-2030)

Chapter 14. Germany Market

  • 14.1. Overview
  • 14.2. Market Revenue, by Type (2017-2030)
  • 14.3. Market Revenue, by Cell Source (2017-2030)
  • 14.4. Market Revenue, by Application (2017-2030)

Chapter 15. France Market

  • 15.1. Overview
  • 15.2. Market Revenue, by Type (2017-2030)
  • 15.3. Market Revenue, by Cell Source (2017-2030)
  • 15.4. Market Revenue, by Application (2017-2030)

Chapter 16. U.K. Market

  • 16.1. Overview
  • 16.2. Market Revenue, by Type (2017-2030)
  • 16.3. Market Revenue, by Cell Source (2017-2030)
  • 16.4. Market Revenue, by Application (2017-2030)

Chapter 17. Italy Market

  • 17.1. Overview
  • 17.2. Market Revenue, by Type (2017-2030)
  • 17.3. Market Revenue, by Cell Source (2017-2030)
  • 17.4. Market Revenue, by Application (2017-2030)

Chapter 18. Spain Market

  • 18.1. Overview
  • 18.2. Market Revenue, by Type (2017-2030)
  • 18.3. Market Revenue, by Cell Source (2017-2030)
  • 18.4. Market Revenue, by Application (2017-2030)

Chapter 19. Japan Market

  • 19.1. Overview
  • 19.2. Market Revenue, by Type (2017-2030)
  • 19.3. Market Revenue, by Cell Source (2017-2030)
  • 19.4. Market Revenue, by Application (2017-2030)

Chapter 20. China Market

  • 20.1. Overview
  • 20.2. Market Revenue, by Type (2017-2030)
  • 20.3. Market Revenue, by Cell Source (2017-2030)
  • 20.4. Market Revenue, by Application (2017-2030)

Chapter 21. India Market

  • 21.1. Overview
  • 21.2. Market Revenue, by Type (2017-2030)
  • 21.3. Market Revenue, by Cell Source (2017-2030)
  • 21.4. Market Revenue, by Application (2017-2030)

Chapter 22. Australia Market

  • 22.1. Overview
  • 22.2. Market Revenue, by Type (2017-2030)
  • 22.3. Market Revenue, by Cell Source (2017-2030)
  • 22.4. Market Revenue, by Application (2017-2030)

Chapter 23. South Korea Market

  • 23.1. Overview
  • 23.2. Market Revenue, by Type (2017-2030)
  • 23.3. Market Revenue, by Cell Source (2017-2030)
  • 23.4. Market Revenue, by Application (2017-2030)

Chapter 24. Brazil Market

  • 24.1. Overview
  • 24.2. Market Revenue, by Type (2017-2030)
  • 24.3. Market Revenue, by Cell Source (2017-2030)
  • 24.4. Market Revenue, by Application (2017-2030)

Chapter 25. Mexico Market

  • 25.1. Overview
  • 25.2. Market Revenue, by Type (2017-2030)
  • 25.3. Market Revenue, by Cell Source (2017-2030)
  • 25.4. Market Revenue, by Application (2017-2030)

Chapter 26. Saudi Arabia Market

  • 26.1. Overview
  • 26.2. Market Revenue, by Type (2017-2030)
  • 26.3. Market Revenue, by Cell Source (2017-2030)
  • 26.4. Market Revenue, by Application (2017-2030)

Chapter 27. South Africa Market

  • 27.1. Overview
  • 27.2. Market Revenue, by Type (2017-2030)
  • 27.3. Market Revenue, by Cell Source (2017-2030)
  • 27.4. Market Revenue, by Application (2017-2030)

Chapter 28. U.A.E. Market

  • 28.1. Overview
  • 28.2. Market Revenue, by Type (2017-2030)
  • 28.3. Market Revenue, by Cell Source (2017-2030)
  • 28.4. Market Revenue, by Application (2017-2030)

Chapter 29. Competitive Landscape

  • 29.1. List of Market Players and their Offerings
  • 29.2. Competitive Benchmarking of Key Players
  • 29.3. Product Benchmarking of Key Players
  • 29.4. Recent Strategic Developments

Chapter 30. Company Profiles

  • 30.1. Smith & Nephew plc
    • 30.1.1. Business overview
    • 30.1.2. Product and service offerings
    • 30.1.3. Key financial summary
  • 30.2. MEDIPOST Co. Ltd.
    • 30.2.1. Business overview
    • 30.2.2. Product and service offerings
    • 30.2.3. Key financial summary
  • 30.3. Anterogen Co. Ltd.
    • 30.3.1. Business overview
    • 30.3.2. Product and service offerings
    • 30.3.3. Key financial summary
  • 30.4. CORESTEM Inc.
    • 30.4.1. Business overview
    • 30.4.2. Product and service offerings
    • 30.4.3. Key financial summary
  • 30.5. PHARMICELL Co. Ltd.
    • 30.5.1. Business overview
    • 30.5.2. Product and service offerings
    • 30.5.3. Key financial summary
  • 30.6. NuVasive Inc.
    • 30.6.1. Business overview
    • 30.6.2. Product and service offerings
    • 30.6.3. Key financial summary
  • 30.7. RTI Surgical Inc.
    • 30.7.1. Business overview
    • 30.7.2. Product and service offerings
    • 30.7.3. Key financial summary
  • 30.8. AlloSource
    • 30.8.1. Business overview
    • 30.8.2. Product and service offerings
    • 30.8.3. Key financial summary
  • 30.9. JCR Pharmaceutical Co. Ltd.
    • 30.9.1. Business overview
    • 30.9.2. Product and service offerings
    • 30.9.3. Key financial summary
  • 30.10. Takeda Pharmaceutical Company Limited
    • 30.10.1. Business overview
    • 30.10.2. Product and service offerings
    • 30.10.3. Key financial summary

Chapter 31. Appendix

  • 31.1. Abbreviations
  • 31.2. Sources and References
  • 31.3. Related Reports